Lucas Ropek's TechCrunch dispatch from the Enhanced Games reads like a business plan with muscles. The so-called "steroid Olympics" in Vegas attracted not just athletes but a specific Silicon Valley orbit of founders, investors, and self-quantifiers who see performance enhancement not as cheating but as an engineering problem. The body, in this framing, is a platform to be optimized. The drug is just the update.
Performance Enhancement as Product-Market Fit
What makes the Enhanced Games culturally significant isn't the steroids. It's the funding thesis underneath them. The event is backed by people who believe that pharmaceutical performance enhancement will be normalized within a decade, and they are positioning accordingly. This is identical logic to every "too early" startup that eventually becomes infrastructure. The athletes aren't just competitors. They are proof of concept. A 2022 paper in JAMA Internal Medicine by Pope et al. found that anabolic steroid use among non-athlete populations has tripled since 2000, a demand curve that any investor would recognize.
The Alumni Capital Behind the Next Body-Tech Wave
The timing is striking. The same week the Enhanced Games made headlines, Snap alumni launched Ghost Angels, a 20-person fund targeting the next generation of social media. Alumni funds are having a moment, which makes sense: people who've watched one consumer behavior shift from fringe to mainstream are well-positioned to bet on the next one. The Enhanced Games crowd would fit neatly into that playbook. Body optimization, once a bodybuilding subculture, is now a consumer vertical with supplement stacks, wearables, and telehealth scripts. TurboFund's healthtech VC list covers the investors most actively funding this collision of biotech and consumer wellness. The line between healthtech and enhancement tech is dissolving faster than anyone expected.